Loading...
Is pramipexole better than placebo for the treatment of mildly to moderately depressed, nondemented people with Parkinson disease (PD)? To find out, researchers conducted a 12-week, double blind, placebo-controlled, multicenter, manufacturer-sponsored trial involving 296 patients with mild-to-moderate depressive symptoms and PD without motor fluctuations.
Pramipexole was statistically superior to placebo in reducing scores on the Beck Depression Inventory (the primary outcome) and on two other depression scales, while also improving motor function. Path analysis suggested that depression benefit was mostly independent of improved motor function. Although improvements on two quality-of-life (QOL) measures correlated with reduced depression, t…